Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q1 2024 · 10-Q
Revenue$3.86B$3.86B+13.8% vs Q1 2023 Net Income$493.00M$493.00M+57.0% vs Q1 2023 EPS Diluted$0.33$0.33+57.1% vs Q1 2023 Gross Profit$2,648,000,000+12.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flow$164,000,000−13.7% Free Cash Flowderived-$15,000,000N/M Margins · derivedGross margin68.7%−0.6 pt vs Q1 2023
Operating margin17.5%+1.2 pt vs Q1 2023
Net margin12.8%+3.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 1, 2024 · 31 d after period end